Top Section/Ad
Top Section/Ad
Most recent
◆ Deal is the fourth EuGB labelled hybrid ◆ Issuer punches through fair value... ◆ ...and gets its tightest senior/sub spread
Abbott Laboratories plundered $20bn as it led a trio of drug companies which printed jumbo bonds as a deluge of supply in the dollar market ensured a red-hot end to the month.
◆ French supermarket chain extends curve to 2035 ◆ Deal lands through fair value ◆ SLB volumes slide despite 'flexibility'
UKPN purchase seen as positive by rating agencies, leads to senior and hybrid upgrades
More articles/Ad
More articles/Ad
More articles
-
Thermo Fisher Scientific, the US genetic testing and laboratory equipment company, has mandated banks for a multi-tranche Reverse Yankee bond in euros. It wants to print fresh debt along its curve out to 30 years. -
ING, which served as agent on a Schuldschein for the first time only five years ago, has carved out an impressive niche in the market, arranging nearly every green issue.
-
Telecom Italia has returned to the Schuldschein market, but through its Italian listed holding company for the first time. Ever since Italy made tax changes for foreign lenders four years ago, Schuldschein arrangers have hoped that more Italian borrowers would come to the market. But companies are coming to the market for price and diversification above anything else.
-
UK coach operator National Express has entered the US private placement market, according to market sources, looking for £200m-equivalent, in dollars, euros and sterling.
-
Indonesian state-owned power company PLN has diversified its funding sources. It debuted in the Samurai market, raising ¥23.2bn ($215m) from three bonds while paying a small premium over its outstanding dollar curve.
-
Nissan has sold upwards of $600m US private placements in the first US PP deal for any Japanese car company, according to several people familiar with the situation. Headline deals from car companies in both European and US private debt markets this year has led market players to believe private investors are taking a rather forgiving approach to the industry’s challenging moment. Silas Brown reports.
